Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma, according to a recent study published in Medical Oncology.
Researchers led by Ilhan Hacibekiroglu of Trakya University in Turkey observed 22 patients with glioblastoma and two patients with World Health Organization III glioma who had been previously treated with temozolomide with radiotherapy and received 10mg/kg bevacizumab intravenously every two weeks until disease progression.
The researchers found that the performance status of 17 patients (70.8 percent) was improved with the bevacizumab regimen. Upon univariate analysis, performance status following bevacizumab therapy was found to be a significant predictor of both progression-free survival (PFS) and overall survival (OS).
In addition, overall response rate was 20.8 percent, with median OS at 6.4 months. Six-month PFS was 37.5 percent and median PFS was 4.1 months.
The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). The data suggest that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS and OS.